long intergenic non-protein coding RNA 1853Genealiases: []
Q-omics provides the consensus-scored LINC01853 profile across patient tissues and cancer cell-line models. LINC01853 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, LINC01853 is differentially expressed in 2, with the highest sampling consensus in KIRP. Additionally, LINC01853 RNA expression shows 10,470 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight LIHC, KIRP, and COAD as cancer lineages where LINC01853 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01853 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01853 survival associations across molecular data types. LINC01853 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01853 RNA expression–survival associations across cancer types. High LINC01853 expression shows unfavorable associations in LIHC, THCA, ACC, KIRC, SARC and BLCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for LINC01853 RNA expression.
This table summarizes LINC01853 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01853. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01853 shows lower tumor expression in KICH and higher tumor expression in KIRP. The KIRP box plot shows higher LINC01853 RNA expression in tumor versus normal tissue (log2 FC = +0.224, t-test p = .024).
This table shows molecular features associated with LINC01853 in patient tissues and cancer cell lines. In patient samples, LINC01853 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
